Sarepta Therapeutics (SRPT) acquires a 26-acre multifunctional manufacturing facility in Massachusetts for ~$25M. It will use the site to make investigational exon skipping therapies for Duchenne muscular dystrophy. The transaction is expected to close in July.
The cGMP-qualified facility was built in 1996 and upgraded in 2006. It will support ~40 techs and support staff.